Inventor · disambiguated record
Markian Stec
Also filed as: STEC MARKIAN · STEC MARKIAN M · STEC MARKIAN MYROSLAW
21 granted patents·7 pending applications·256 citations·filing 2002–2023
95Inventor score
Top patents by PatentIndex Score
28 records- 0197US10300075B2Compounds that inhibit MCL-1 proteinAMGEN INC·Filed 2018·Granted May 28, 2019·22 cites·39 claims
- 0294US7820665B2Imidazopyridazine inhibitors of PI3 kinase for cancer treatmentAMGEN INC·Filed 2008·Granted Oct 26, 2010·38 cites·9 claims
- 0393US10632128B2Compounds that inhibit Mcl-1 proteinAMGEN INC·Filed 2019·Granted Apr 28, 2020·5 cites·49 claims
- 0493US9066954B2Fused heterocyclic derivatives and methods of useAMGEN INC·Filed 2013·Granted Jun 30, 2015·22 cites·9 claims
- 0592US8524900B2Fused heterocyclic derivatives and methods of useALBRECHT BRIAN K·Filed 2011·Granted Sep 3, 2013·23 cites·8 claims
- 0692US7115607B2Substituted piperazinyl amides and methods of useAMGEN INC·Filed 2002·Granted Oct 3, 2006·42 cites·14 claims
- 0792US6995162B2Substituted alkylamine derivatives and methods of useAMGEN INC·Filed 2002·Granted Feb 7, 2006·48 cites·26 claims
- 0891US10500213B2Compounds that inhibit Mcl-1 proteinAMGEN INC·Filed 2019·Granted Dec 10, 2019·6 cites·46 claims
- 0986US8642624B2Substituted alkylamine derivatives and methods of useCHEN GUOQING·Filed 2011·Granted Feb 4, 2014·11 cites·3 claims
- 1084US7053088B2Vanilloid receptor ligands and their use in treatmentsAMGEN INC·Filed 2003·Granted May 30, 2006·19 cites·22 claims
- 1182US7396831B2Vanilloid receptor ligands and their use in treatmentsAMGEN INC·Filed 2005·Granted Jul 8, 2008·5 cites·21 claims
- 1278US7301022B2Vanilloid receptor ligands and their use in treatmentsAMGEN INC·Filed 2006·Granted Nov 27, 2007·4 cites·11 claims
- 1377US7144888B2Vanilloid receptor ligands and their use in treatmentsAMGEN INC·Filed 2003·Granted Dec 5, 2006·9 cites·25 claims
- 1472US11224601B1Compounds that inhibits MCL-1 proteinAMGEN INC·Filed 2020·Granted Jan 18, 2022·0 cites·15 claims
- 1572US7148221B2Vanilloid receptor ligands and their use in treatmentsAMGEN INC·Filed 2005·Granted Dec 12, 2006·1 cites·19 claims
- 1669US10821115B2Compounds that inhibit Mcl-1 proteinAMGEN INC·Filed 2020·Granted Nov 3, 2020·0 cites·43 claims
- 1769US9550762B2Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of useAMGEN INC·Filed 2015·Granted Jan 24, 2017·1 cites·95 claims
- 1859US2025115622A1Crystalline Forms Of An MCL-1 InhibitorAMGEN INC·Filed 2023·Application pending·0 cites
- 1958US2013273004A1Substituted alkylamine derivatives and methods of useAMGEN INC·Filed 2013·Application pending·0 cites
- 2054US7524874B2Vanilloid receptor ligands and their use in treatmentsAMGEN INC·Filed 2005·Granted Apr 28, 2009·0 cites·19 claims
- 2154US7332511B2Vanilloid receptor ligands and their use in treatmentsAMGEN INC·Filed 2005·Granted Feb 19, 2008·0 cites·19 claims
- 2253US2023312606A1Mcl-1 inhibitor formulationsAMGEN INC·Filed 2021·Application pending·0 cites
- 2349US8314087B2Nitrogen-containing heterocyclyl ketones and methods of useALBRECHT BRIAN K·Filed 2008·Granted Nov 20, 2012·0 cites·6 claims
- 2447US2012107275A1Fused heterocyclic derivatives and methods of useALBRECHT BRIAN K·Filed 2011·Application pending·0 cites
- 2546US2017267673A1Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of useAMGEN INC·Filed 2016·Application pending·0 cites
- 2640US2023117777A1Methylation of mcl-1 compoundsAMGEN INC·Filed 2021·Application pending·0 cites
- 2733US2012190666A1Heteroaryl Compounds as PIKK InhibitorsBODE CHRISTIANE·Filed 2010·Application pending·0 cites
- 2830US8431563B2Compounds that interact with glucokinase regulatory protein for the treatment of diabetesASHTON KATE·Filed 2011·Granted Apr 30, 2013·0 cites·34 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →